Devos, Sophie
Bonnet, Fabrice
Hessamfar, Mojgan
Neau, Didier
Vareil, Marc-Olivier
Leleux, Olivier
Cazanave, Charles
Rouanes, Nicolas
Duffau, Pierre
Lazaro, Estibaliz
Dabis, François
Wittkop, Linda
Barger, Diana
Bellecave, P.
Blanco, P.
Bouchet, S.
Breilh, D.
Desjardin, S.
Gaborieau, V.
Gimbert, A.
Lacaze-Buzy, L.
Lacoste, D.
Lafon, M. E.
Lawson-Ayayi, S.
Le Marec, F.
Le Moal, G.
Malvy, D.
Marchand, L.
Mercié, P.
Pellegrin, I.
Perrier, A.
Petrov-Sanchez, V.
Bernard, N.
Bronnimann, D.
Chaussade, H.
Dondia, D.
Faure, I.
Morlat, P.
Mériglier, E.
Paccalin, F.
Riebero, E.
Rivoisy, C.
Vandenhende, M. A.
Barthod, L.
Dauchy, F. A.
Desclaux, A.
Ducours, M.
Dutronc, H.
Duvignaud, A.
Leitao, J.
Lescure, M.
Nguyen, D.
Pistone, T.
Puges, M.
Wirth, G.
Courtault, C.
Camou, F.
Greib, C.
Pellegrin, J. L.
Rivière, E.
Viallard, J. F.
Imbert, Y.
Thierry-Mieg, M.
Rispal, P.
Caubet, O.
Ferrand, H.
Tchamgoué, S.
Farbos, S.
Wille, H.
Andre, K.
Caunegre, L.
Gerard, Y.
Osorio-Perez, F.
Chossat, I.
Iles, G.
Labasse-Depis, M.
Lacassin, F.
Barret, A.
Castan, B.
Koffi, J.
Saunier, A.
Zabbe, J. B.
Dumondin, G.
Beraud, G.
Catroux, M.
Garcia, M.
Giraud, V.
Martellosio, JP.
Roblot, F.
Pasdeloup, T.
Riché, A.
Grosset, M.
Males, S.
Ngo Bell, C.
Carpentier, C.
Tumiotto, C.
Miremeont-Salamé, G.
Arma, D.
Arnou, G.
Blaizeau, M. J.
Camps, P.
Decoin, M.
Delveaux, S.
Diarra, F.
Gabrea, L.
Lai, W. H.
Lenaud, E.
Plainchamps, D.
Pougetoux, A.
Uwamaliya, B.
Zara, K.
Conte, V.
Gapillout, M.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Tobacco, alcohol, cannabis, and illicit drug use and their association with CD4/CD8 cell count ratio in people with controlled HIV: a cross-sectional study (ANRS CO3 AQUIVIH-NA-QuAliV)
https://doi.org/10.1186/s12879-022-07963-6
Funding for this research was provided by:
Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ECTZ100440 2019-2)
Article History
Received: 30 May 2022
Accepted: 21 December 2022
First Online: 9 January 2023
Declarations
:
: The ANRS CO3 Aquitaine-AQUIVIH-NA cohort study was approved by an Institutional Review Board on May 27, 2016 and the QuAliV study was granted ethical approval in August 2017. The National Commission on Informatics and Liberty (CNIL), the French regulatory agency charged with enforcing data privacy laws, reviewed and approved QuAliV study-specific amendments to authorizations on March 12, 2018. Written and informed consent is required of all cohort participants. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: SD, MH, DN, NR, EL, PD, CC, OL, FD, LW have no relevant financial or non-financial competing interests to disclose. MOV reports financial support from Gilead Sciences, ViiV Healthcare and MSD outside the submitted work (conference participation). FB reports non-financial support from Gilead Sciences, Janssen, ViiV Healthcare, and MSD, personal fees from Gilead Sciences, Janssen, ViiV Healthcare and MSD outside the submitted work. DB has received speaking fees from Gilead Sciences, ViiV Healthcare, and MSD and been compensated as an expert on a Gilead Sciences advisory board outside the submitted work.